drugset / Trial / NCT02732522

Comparison Between Vaginal and Sublingual Misoprostol 50 µg for Cervical Ripening Prior to Induction of Labor

NCT02732522

Phase 4 Completed 102 enrolled University of the Republic
RandomizedParallel-groupSingle-blindTreatment

Summary

To analyze whether there is a statistically significant difference in the modifications present in the uterine cervix 6 hours after administration of misoprostol 50 µg through vaginal versus sublingual routes.

Timeline

Start
2014-10
Primary completion
2015-05
Completion
2016-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Misoprostol Other / unclassified 50 ug Other

Indications